FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010

Published on August 28, 2025
FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.
Continue reading on website
Other news

Deepcove Optical and Optiswiss extend distribution agreement

August 28, 2025
The new long-term agreement confirms Deepcove Optical as the exclusive UK distribution partner for Optiswiss lenses

Japan rings in first soft contact lens for myopia control with MiSight 1 day approval

August 28, 2025
The Japan’s Ministry of Health, Labor, and Welfare approved the lens for manufacturing and sale in the country.